Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical company specializing in treatments for hematologic diseases, has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The company's management will engage in a fireside chat on Tuesday, May 20th at 9:00 am ET. Investors can access the live webcast through Disc Medicine's investor relations website at ir.discmedicine.com, with an archived replay available after the event.
Disc Medicine (NASDAQ:IRON), un'azienda biofarmaceutica in fase clinica specializzata in trattamenti per malattie ematologiche, ha annunciato la sua partecipazione al 3° Annuale BioConnect Investor Conference di H.C. Wainwright. Il management della società parteciperà a una conversazione informale il martedì 20 maggio alle 9:00 ET. Gli investitori potranno seguire la diretta streaming tramite il sito web per gli investitori di Disc Medicine all'indirizzo ir.discmedicine.com, con una registrazione disponibile dopo l'evento.
Disc Medicine (NASDAQ:IRON), una empresa biofarmacéutica en etapa clínica especializada en tratamientos para enfermedades hematológicas, ha anunciado su participación en la 3ª Conferencia Anual BioConnect para Inversionistas de H.C. Wainwright. La dirección de la compañía participará en una charla informal el martes 20 de mayo a las 9:00 am ET. Los inversores podrán acceder a la transmisión en vivo a través del sitio web de relaciones con inversionistas de Disc Medicine en ir.discmedicine.com, con una repetición archivada disponible después del evento.
Disc Medicine (NASDAQ:IRON)은 혈액 질환 치료에 특화된 임상 단계 바이오제약 회사로, H.C. Wainwright 제3회 연례 BioConnect 투자자 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 5월 20일 화요일 오전 9시(동부 시간)에 파이어사이드 채팅에 참여할 예정입니다. 투자자들은 Disc Medicine 투자자 관계 웹사이트 ir.discmedicine.com을 통해 라이브 웹캐스트를 시청할 수 있으며, 행사 후에는 녹화 영상도 제공됩니다.
Disc Medicine (NASDAQ:IRON), une société biopharmaceutique en phase clinique spécialisée dans les traitements des maladies hématologiques, a annoncé sa participation à la 3e conférence annuelle BioConnect pour investisseurs de H.C. Wainwright. La direction de l'entreprise participera à une discussion informelle le mardi 20 mai à 9h00 ET. Les investisseurs pourront accéder à la diffusion en direct via le site web des relations investisseurs de Disc Medicine à ir.discmedicine.com, avec une rediffusion disponible après l'événement.
Disc Medicine (NASDAQ:IRON), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung hämatologischer Erkrankungen spezialisiert hat, hat seine Teilnahme an der 3. jährlichen BioConnect Investor Conference von H.C. Wainwright bekannt gegeben. Das Management des Unternehmens wird am Dienstag, den 20. Mai um 9:00 Uhr ET an einem Fireside Chat teilnehmen. Investoren können den Live-Webcast über die Investor-Relations-Website von Disc Medicine unter ir.discmedicine.com verfolgen; eine Aufzeichnung wird nach der Veranstaltung verfügbar sein.
- None.
- None.
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20th at 9:00 am ET.
A live webcast of the fireside chat will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.
About Disc Medicine
Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.
Media Contact
Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com
Investor Relations Contact
Christina Tartaglia
Precision AQ
christina.tartaglia@precisionaq.com
FAQ
When is Disc Medicine (IRON) presenting at the H.C. Wainwright BioConnect Conference?
How can investors watch Disc Medicine's (IRON) presentation at the H.C. Wainwright Conference?
What is Disc Medicine's (IRON) main business focus?
What type of event will Disc Medicine (IRON) participate in at the H.C. Wainwright Conference?
